Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Diltiazem
Drug ID BADD_D00674
Description Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization.[L10556] Compared to dihydropyridine drugs, such as [nifedipine], that preferentially act on vascular smooth muscle and [verapamil] that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle.[T28] Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent [L6289] for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation, atrial flutter. Apart from its main FDA-approved indications, diltiazem has also been used for numerous off-label indications, such as anal fissures (in topical formulations), migraine prophylaxis, pulmonary hypertension, and rest-related cramps in the lower extremities.[L6289] Typically available in extended-release oral and intravenous formulations, diltiazem is marketed under various brand names with Cardizem and Tiazac being the most common ones.
Indications and Usage For the treatment of Hypertension
Marketing Status Prescription; Discontinued
ATC Code C05AE03; C08DB01
DrugBank ID DB00343
KEGG ID D07845
MeSH ID D004110
PubChem ID 39186
TTD Drug ID D0OB1J
NDC Product Code Not Available
Synonyms Diltiazem | Cardil | Cardizem | CRD-401 | CRD 401 | CRD401 | Tiazac | Dilacor XR | Dilren | Diltiazem Hydrochloride | Diltiazem Malate | Dilzem | Aldizem | Dilacor
Chemical Information
Molecular Formula C22H26N2O4S
CAS Registry Number 56209-45-1
SMILES CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Crohn's disease07.08.01.015; 10.02.01.0050.000184%Not Available
Crystalluria20.02.01.003--Not Available
Cystitis11.01.14.001; 20.03.02.002--
Death08.04.01.001--
Depression19.15.01.001--
Dermatitis23.03.04.0020.000369%Not Available
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004--Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.003--Not Available
Dissociation19.14.01.002--Not Available
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.0070.000553%
Drug abuse19.07.02.0100.000144%Not Available
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.000184%Not Available
Drug hypersensitivity10.01.01.0010.001476%Not Available
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.000461%
Dyspnoea02.01.03.002; 22.02.01.004--
Ear pain04.03.01.003--
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002--Not Available
Eczema infected11.01.12.010; 23.03.04.0210.000184%Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Electrocardiogram QT prolonged13.14.05.0040.000369%
Electrocardiogram ST segment elevation13.14.05.025--Not Available
Endophthalmitis06.04.05.009; 11.01.06.003--
Epistaxis22.04.03.001; 24.07.01.005--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene